Gilead recalls Veklury lot due to glass contamination
- Gilead Sciences has recalled Veklury lot # 47035CFA due to glass particles found in vials.
- The recall was initiated after a customer complaint and subsequent investigation confirmed contamination.
- No adverse events have been reported, but the recall underscores the importance of product safety in healthcare.
Gilead Sciences has initiated a voluntary recall of a specific lot of its COVID-19 treatment, Veklury (remdesivir), after receiving a customer complaint regarding the presence of glass particles in the vials. The affected lot, identified as # 47035CFA, was distributed nationwide starting July 16, 2024. Following the investigation, the company confirmed the contamination, prompting immediate action to ensure patient safety. To address the issue, Gilead is notifying distributors and customers via UPS next-day air mail, instructing pharmacies to stop using the affected lot and return any remaining vials. The company is taking all necessary measures to facilitate the recall process and mitigate potential health risks associated with the contaminated product. The administration of contaminated injectables can lead to serious health complications, including local irritation, swelling, and the risk of glass particles obstructing blood vessels, which could result in strokes or even fatalities. Fortunately, Gilead has reported no adverse events linked to this recall thus far. Veklury is intended for treating COVID-19 in both adults and pediatric patients, particularly those hospitalized or at high risk of severe disease progression. The recall comes at a time when Veklury sales have seen a decline, attributed to lower COVID-19 hospitalization rates, highlighting the ongoing challenges faced by pharmaceutical companies in managing product safety and market demand.